![Janux Therapeutics, Inc. logo](/logos/JANX.webp)
Janux Therapeutics, Inc.
NASDAQ:JANX
Overview | Financials
Company Name | Janux Therapeutics, Inc. |
Symbol | JANX |
Currency | USD |
Price | 41.26 |
Market Cap | 2,152,307,270 |
Dividend Yield | 0% |
52-week-range | 5.65 - 65.6 |
Industry | Biotechnology |
Sector | Healthcare |
CEO | Dr. David Alan Campbell Ph.D. |
Website | https://www.januxrx.com |
An error occurred while fetching data.
About Janux Therapeutics, Inc.
Janux Therapeutics, Inc., a biopharmaceutical company, develops therapeutics based on proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to treat patients suffering from cancer. The company's lead TRACTr product candidates that are in preclinical or discovery stage target prostate-specific membrane antigen, epidermal growth factor receptor, and trophoblast cell surface
Related Stocks
Financials
Numbers are in millions USD
Numbers are in millions USD